Everything below concerns counterion. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-27. Numbers and descriptions here follow the published literature rather than marketing material.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
In the mid-1990s the NHS in the UK took the bold step of making this a universal feature of result delivery to general practice (GPs) and embarked on two linked projects to achieve this. In the first, the Pathology Messaging Enabler Project, standards were defined and infrastructure installed to link 200 laboratory systems to 8,500 GP systems. In the second project, the Pathology Messaging Implementation Project, these standards and the associated software was rolled out. By 2004 more than 35 million results messages were being transmitted each year and in 2007 some 50 million such messages were safely and securely delivered. During the 12 months to July 2023, 1.88 Billion discrete new EPR items added to electronic patient records held by UK GPs were expressed using a code from within the PBCL, accompanied (usually) by a value and a unit of measurement. The PMIP EDIFACT+PBCL system remains the prevailing technology supporting all GP laboratory requesting and resulting across the entire UK, but the strategic national intent since the early 2020s has been to migrate all live GP systems to FHIR and the Unified Test List, a new and bespoke national extension of SNOMED CT offering greater detail. Although it is hoped this migration will remove the discordant standards used between UK primary and secondary care, as of August 2024 the migration has yet to begin.
In May 2006, Valve announced a trilogy of episodic games that would continue the Half-Life 2 story, with the final episode planned for release by Christmas 2007. Valve's president, Gabe Newell, said the approach would allow Valve to release products more quickly after the six-year Half-Life 2 development, and that he considered the trilogy the equivalent of Half-Life 3. According to Newell, where Half-Life saw the G-Man transform Freeman into his tool, and Half-Life 2 saw Freeman being used by G-Man, the episodes would see G-Man lose control. Episode One was released on June 1, 2006. The player controls Freeman as he and Alyx escape City 17 before a dark energy reactor core destroys it. It introduced several graphical effects, including new lighting features and more advanced facial animation. The story focuses on Alyx. Episode One received a generally positive critical reaction, although the short length was a common point of criticism.
== Interactions == Valproate inhibits CYP2C9, glucuronyl transferase, and epoxide hydrolase and is highly protein bound and hence may interact with drugs that are substrates for any of these enzymes or are highly protein bound themselves. It may also potentiate the CNS depressant effects of alcohol. It should not be given in conjunction with other antiepileptics due to the potential for reduced clearance of other antiepileptics (including carbamazepine, lamotrigine, phenytoin and phenobarbital) and itself. It may also interact with:
Sources: en.wikipedia.org
motif Any distinctive or recurring sequence of nucleotides in a nucleic acid or of amino acids in a peptide that is or is conjectured to be biologically significant, especially one that is reliably recognized by other biomolecules or which has a three-dimensional structure that permits unique or characteristic chemical interactions such as DNA binding. In nucleic acids, motifs are often short (three to ten nucleotides in length), highly conserved sequences which act as recognition sites for DNA-binding proteins or RNAs involved in the regulation of gene expression.
== Early life, family, and education == Pritzker was born in Palo Alto, California, on January 19, 1965. He is the son of Donald Pritzker and Sue Pritzker (née Sandel). Pritzker is named after his paternal uncles, Jay Pritzker and Robert Pritzker, and is known by his initials ("JB" for "Jay Bob"). He has two older siblings: Anthony and Penny, the latter of whom served as the United States Secretary of Commerce under Barack Obama. Pritzker is a member of the Pritzker family, a Jewish family of Ukrainian descent that was prominent in business and philanthropy during the late 20th century. The Pritzkers have consistently ranked near the top of the Forbes "America's Richest Families" list since its inception in 1982. Pritzker was raised in Atherton, California. His father, Donald, was the president of Hyatt, a hotel chain owned by the Pritzker family. Donald was credited with growing Hyatt into the nation's fifth-largest hotel chain at the time of his death. Pritzker's parents were also active in Democratic politics in California. Pritzker later credited this exposure with spurring his own interest in politics. In 1972, Donald Pritzker died of a heart attack at age 39. After his father died, Pritzker's mother struggled with alcoholism and depression. As a result, at age 12, Pritzker moved to Chicago to live with his aunt and uncle, Jay and Cindy Pritzker. He graduated from Milton Academy, a boarding school in Massachusetts, and attended Georgetown University before transferring to Duke University, from which he graduated with a Bachelor of Arts in political science.
== External links == Book page on McSweeny's Archived 2013-05-14 at the Wayback Machine Dani Shapiro on Half a Life in The New York Times Book Review Strauss with Sam Tanenhaus of The New York Times Book Review Archived 2012-04-05 at the Wayback Machine Strauss and "Guilty as Not Charged" on This American Life Poets & Writers on Darin Strauss and Half a Life
===== Linear or reticular opacities ===== Acute: Pulmonary edema Chronic: Idiopathic pulmonary fibrosis Connective tissue-associated interstitial lung diseases Asbestosis Sarcoidosis Hypersensitivity pneumonitis Drug-induced lung disease
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.